Access and Reimbursement

For Your Practice

XGEVA® has confirmed coverage nationwide, and claims are paid in a timely manner.1-3


In patients with bone metastases from solid tumors receiving XGEVA® for the prevention of skeletal-related events:

*Data as of October 2013.

Based on analysis of XGEVA® coverage by 65 US commercial plans with 178 million lives; data as of October 2013. 3% of commercial lives may have restrictions based on other criteria, such as Eastern Cooperative Oncology Group (ECOG) performance status or tumor types.

Based on analysis of 3,071 Medicare claims (from February 2011 to February 2012) and 1,856 commercial claims (from January 2011 to February 2012) for XGEVA® through February 2012.

Amgen Assist® provides comprehensive support services

Access Reimbursement Services
AmgenAssistOnline.com

Tap to call The Safety Net
Foundation 1-888-SN-AMGEN
(1-888-762-6436)

XGEVA® J-CODE: J0897

Indication

XGEVA® (denosumab) is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors.

XGEVA® is not indicated for the prevention of skeletal-related events in patients with multiple myeloma.

Important Safety Information

Hypocalcemia

Hypersensitivity

Drug Products with Same Active Ingredient

Osteonecrosis of the Jaw (ONJ)

Atypical Subtrochanteric and Diaphyseal Femoral Fracture

Embryo-Fetal Toxicity

Adverse Reactions

Please see Full Prescribing Information

References

  1. Data on file, Amgen.

  2. Data on file, Amgen.

  3. Data on file, Amgen.

Back to top

Indication and Important Safety Information

XGEVA® is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors. XGEVA® is not indicated for the prevention of skeletal-related events in patients with multiple myeloma. Read More